Danuglipron vs Orforglipron
How Danuglipron and Orforglipron compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Danuglipron and Orforglipron come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Danuglipron vs Orforglipron, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Danuglipron | Orforglipron |
|---|---|---|
| What it is | Non-peptide small-molecule GLP-1 receptor agonist (an oral drug, not a peptide) | Non-peptide small-molecule GLP-1 receptor agonist (an oral drug, not a peptide) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Type 2 diabetes; Chronic weight management | Chronic weight management (obesity or overweight with a comorbidity) |
| US regulatory status (2026) | withdrawn (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Chronic weight management |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 48 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Danuglipron produced the expected GLP-1 gastrointestinal adverse events, with high discontinuation rates in the obesity trial. Pfizer reported that liver enzyme elevations across more than 1,400 participants were in line with approved drugs in the class, but one asymptomatic potential drug-induced liver injury resolved after stopping treatment and led Pfizer to end development. | Orforglipron cleared FDA review, so unlike most compounds on this site it has a real human safety record. Its side effects are the familiar GLP-1 class pattern — mostly gut-related (nausea, diarrhea, vomiting, constipation), usually mild to moderate and often easing as the body adjusts. Long-term, real-world safety data are still accumulating, as they are for every drug in this young class. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Danuglipron vs Orforglipron: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Orforglipron
Orforglipron is FDA-approved (as of Jul 2026); Danuglipron is withdrawn in the US, so it isn't available as an approved prescription.